4-Chloro-3-nitroanisole | CAS:10298-80-3

We serve 4-Chloro-3-nitroanisole CAS:10298-80-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Chloro-3-nitroanisole

Chemical Name:4-Chloro-3-nitroanisole
CAS.NO:10298-80-3
Synonyms:4-Chloro-3-nitroanisole
1-chloro-4-methoxy-2-nitrobenzene
2-Nitro-4-methoxychlorobenzene
2-CHLORO-5-METHOXYNITROBENZENE
4-Chlor-3-nitro-anisol
 
Physical and Chemical Properties:
Density 1.4±0.1 g/cm3
Boiling Point 293.3±20.0 °C at 760 mmHg
Melting Point 41-43 °C(lit.)
Molecular Formula C7H6ClNO3
Molecular Weight 187.580
Flash Point 131.2±21.8 °C
Vapour Pressure 0.0±0.6 mmHg at 25°C
Index of Refraction 1.560
 
Specification:
Appearance:Light yellow crystalline powder
Assay(HPLC):≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Iguratimod(CAS:123663-49-0).



Contact us for information like 4-Chloro-3-nitroanisole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Chlor-3-nitro-anisol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Chlor-3-nitro-anisol Use and application,4-Chlor-3-nitro-anisol technical grade,usp/ep/jp grade.


Related News: Capacity: the bottleneck of business growth, expanding capacity and increasing utilization become a trend. Capacity is the core factor that determines the supply capacity of API companies. Insufficient capacity will cause companies to selectively complete orders and produce varieties, limiting the expansion of API products and market development.beta-Hydroxybutyric acid sodium salt manufacturer Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).2-Bromo-5-cyanopyridine supplier Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).(2R,3S)-N-Benzoyl-3-phenyl Isoserine vendor During the deadly SARS pandemic of the early 2000s, another traditional Chinese herbal medicine, Banlangen, made from the root of a flowering woad plant and used to treat the common cold, was sold out in many pharmacies due to a popular but clinically unproven belief that it could help prevent SARS, which is closely related to the Wuhan coronavirus.During the deadly SARS pandemic of the early 2000s, another traditional Chinese herbal medicine, Banlangen, made from the root of a flowering woad plant and used to treat the common cold, was sold out in many pharmacies due to a popular but clinically unproven belief that it could help prevent SARS, which is closely related to the Wuhan coronavirus.